论文部分内容阅读
应用免疫组织化学ＡＢＣ、Ｓ－Ｐ法对１０２例卵巢肿瘤进行ｃ－ｅｒｂＢ－２、ｐ５３表达的研究。结果显示：１）１０２例卵巢肿瘤ｃ－ｅｒｂＢ－２表达阳性率为７０．５％，恶性及交界性肿瘤阳性表达率明显高于良性肿瘤，有统计学差异，其中浆液性囊腺癌阳性率为８１．５％，高于浆液性囊腺瘤的３７．５％（Ｐ＜０．０５）。２）１０２例卵巢肿瘤ｐ５３阳性率为６７．６４％，其中粘液性囊腺癌及交界瘤阳性率分别为７２．７％、７０％，高于粘液性囊腺瘤的４０％，但无统计学差异（Ｐ＞０．０５）。３）ｃ－ｅｒｂＢ－２、ｐ５３在卵巢肿瘤中的表达有协同作用，同时表达占５１．９６％，其中４８例卵巢癌随访其表达率与预后有关。提示ｃ－ｅｒｂＢ－２、ｐ５３联合检测有利于卵巢肿瘤的早期诊断和评估预后。
Immunohistochemical ABC and S-P methods were used to study the expression of c-erbB-2 and p53 in 102 cases of ovarian tumors. The results showed that: 1) The positive rate of c-erbB-2 expression in 102 cases of ovarian tumors was 70.5%. The positive rate of malignant and borderline tumors was significantly higher than that of benign tumors. There was a statistically significant difference, and the positive rate of serous cystadenocarcinoma was statistically significant. It was 81.5% higher than 37.5% of serous cystadenoma (P<0.05). 2) The positive rate of p53 in 102 cases of ovarian tumors was 67.64%. The positive rates of mucinous cystadenocarcinoma and borderline tumors were 72.7% and 70%, respectively, which were higher than 40% of mucinous cystadenoma, but there was no statistics. Differences in learning (P>0.05). 3) The expression of c-erbB-2 and p53 had a synergistic effect in ovarian tumors. The expression of c-erbB-2 and p53 at the same time accounted for 51.96%. The expression rate of 48 cases of ovarian cancer was related to its prognosis. It is suggested that the combined detection of c-erbB-2 and p53 is beneficial to the early diagnosis and prognosis of ovarian tumors.